Cancer nanomedicines: So many papers and so few drugs
This review identifies a timeline to nanomedicine anticancer drug approval using the business model of inventors, innovators and imitators. By evaluating the publication record of nanomedicine cancer therapeutics we identified a trend of very few publications prior to FDA approval. We first enumerat...
Saved in:
Published in | Advanced drug delivery reviews Vol. 65; no. 1; pp. 80 - 88 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.01.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!